Last updated: February 17, 2026
Development Status
KBP-5074 is a selective aldosterone synthase inhibitor under development by Kadmon Holdings aimed at conditions like resistant hypertension and fluid retention associated with chronic kidney disease (CKD). As of the latest updates, the drug is in phase 2 clinical trials. The primary focus involves evaluating its efficacy, safety, and tolerability in hypertensive patients with CKD.
- Phase 2 Trials: Recruitment completed in multiple studies assessing blood pressure reduction and safety profile. Data readouts are expected by Q2 2023.
- Regulatory Interactions: Preliminary discussions with the FDA are ongoing, with a potential IND submission targeted for Q4 2023.
- Key Differentiator: KBP-5074's selectivity for aldosterone synthase minimizes off-target effects compared to non-selective mineralocorticoid receptor antagonists.
Clinical Development Timeline
| Milestone |
Expected Date |
Notes |
| Completion of phase 2 data |
Q2 2023 |
Initial efficacy and safety results expected |
| Regulatory submission (IND) |
Q4 2023 |
Submission for phase 3 planning |
| Phase 3 initiation |
Q2 2024 |
Pending results from phase 2 |
| Phase 3 completion |
2025 |
Data required for NDA submission |
Market Projection
Market Size and Growth
The global hypertension market was valued at $53 billion in 2022 and is projected to grow at a compound annual growth rate (CAGR) of 5.8% through 2030. The subset focusing on resistant hypertension and CKD accounts for approximately 20% of this total, estimated at $10.6 billion in 2022, with a CAGR of 7%.
Key Market Drivers
- Increase in CKD prevalence, driven by diabetes and hypertension.
- Growing adoption of mineralocorticoid receptor antagonists and aldosterone synthase inhibitors.
- Unmet need for drugs with improved safety profiles, especially in elderly and comorbid populations.
Competitive Landscape
| Candidate/Drug |
Mechanism |
Development Stage |
Marketed? |
Key Differentiator |
| Eplerenone |
Mineralocorticoid receptor blocker |
Marketed |
Yes |
Selectivity reduces hyperkalemia |
| Finerenone |
Non-steroidal mineralocorticoid receptor antagonist |
Marketed |
Yes |
Favorable safety profile in CKD patients |
| Esaxerenone |
Mineralocorticoid receptor blocker |
Marketed/Phase 3 |
Yes |
Potentially superior blood pressure control |
| KBP-5074 |
Aldosterone synthase inhibitor |
Phase 2 |
No |
Higher selectivity, potentially fewer side effects |
Revenue Projections
Assuming successful phase 3 development and regulatory approval around 2025, KBP-5074 could capture a significant market share owing to its differentiated profile. Conservative estimates predict peak annual sales of $2 billion within 7 years post-launch, assuming a 10% penetration of the resistant hypertension and CKD segments.
Regulatory and Commercial Risks
- Delays or failures in phase 2 or phase 3 trials could postpone or prevent approval.
- Competition from existing drugs with established market presence.
- Safety concerns emerging during late-stage trials could hinder approval.
- Price elasticity and payer reimbursement policies could impact market penetration.
Summary
KBP-5074 is progressing through phase 2 trials with anticipated data in Q2 2023. The drug’s selectivity offers a potential edge over current standard therapies. The resistant hypertension and CKD markets offer sizable growth opportunities, especially as unmet needs persist despite existing treatments. Success hinges on positive trial outcomes and efficient regulatory navigation.
Key Takeaways
- KBP-5074 is a selective aldosterone synthase inhibitor in phase 2, targeting resistant hypertension and CKD.
- Market potential exceeds $10 billion globally, driven by rising CKD and hypertension prevalence.
- Competitive landscape includes eplerenone, finerenone, and esaxerenone, with KBP-5074 distinguished by its selectivity.
- Positive phase 2 data and regulatory approval in 2025 could lead to peak sales of $2 billion annually.
- Risks include clinical trial delays, safety issues, and market competition.
FAQs
-
What differentiates KBP-5074 from existing mineralocorticoid receptor antagonists?
KBP-5074 selectively inhibits aldosterone synthase, potentially reducing off-target effects such as hyperkalemia, common with non-selective antagonists.
-
When are phase 2 trial results expected?
Readouts are anticipated in Q2 2023.
-
What are the main indications for KBP-5074?
Resistant hypertension and fluid retention in chronic kidney disease.
-
What challenges could hinder KBP-5074’s market entry?
Delays in clinical trials, safety concerns, or poor efficacy data.
-
How does the competitive landscape look for KBP-5074?
Several marketed drugs exist, but KBP-5074’s selectivity may offer clinical advantages.
Sources
[1] Kadmon Holdings Inc. Clinical trial registry, 2023.
[2] Market data: Grand View Research, 2022.
[3] Industry reports: EvaluatePharma, 2023.
